You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCeritinib
Accession NumberDB09063
TypeSmall Molecule
GroupsApproved
DescriptionCeritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.
Structure
Thumb
Synonyms
céritinib
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
External Identifiers
  • LDK 378
  • LDK-378
  • LDK378
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Zykadiacapsule150 mg/1oralNovartis Pharmaceuticals Corporation2014-04-29Not applicableUs
Zykadiacapsule150 mgoralNovartis Pharmaceuticals Canada Inc2015-04-29Not applicableCanada
ZykadiaCapsule, hard150 mgOral useNovartis Europharm Ltd2015-05-06Not applicableEu
ZykadiaCapsule, hard150 mgOral useNovartis Europharm Ltd2015-05-06Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIK418KG2GET
CAS number1032900-25-6
WeightAverage: 558.135
Monoisotopic: 557.22273844
Chemical FormulaC28H36ClN5O3S
InChI KeyVERWOWGGCGHDQE-UHFFFAOYSA-N
InChI
InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
IUPAC Name
5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine
SMILES
CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationCeritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
PharmacodynamicsNot Available
Mechanism of actionCeritinib inhibits Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), which is an enzyme that in humans is encoded by the ALK gene. About 4-5% of NSCLCs have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Ceritinib has been shown to inhibit in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats.
Related Articles
AbsorptionAfter oral administration of ceritinib, peak concentrations were achieved after approximately 4 to 6 hours.
Volume of distribution

The apparent volume of distribution (Vd/F) is 4230 L following a single 750 mg dose.

Protein bindingCeritinib is 97% bound to human plasma proteins, independent of drug concentration.
Metabolism

In vitro studies demonstrated that CYP3A was the major enzyme involved in the metabolic clearance of ceritinib. Following oral administration of a single 750 mg radiolabeled ceritinib dose, ceritinib as the parent compound was the main circulating component (82%) in human plasma.

Route of eliminationFollowing oral administration of a single 750 mg radiolabeled ceritinib dose, 92.3% of the administered dose was recovered in the feces (with 68% as unchanged parent compound) while 1.3% of the administered dose was recovered in the urine.
Half lifeThe terminal half life is 41 hours.
Clearance

The geometric mean apparent clearance (CL/F) of ceritinib was lower at steady-state (33.2 L/h) after 750 mg daily dosing than after a single 750 mg dose (88.5 L/h).

ToxicityThere is not currently any data on carcinogenicity, effect on human fertility, or on early embryonic development. However, based on its mechanism of action, ceritinib may cause fetal harm when administered to pregnant women and should therefore be administered with effective contraception during treatment. Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients. Drug-induced hepatotoxicity also occurred in 27% of 255 patients, presenting as alanine aminotransferase (ALT) levels greater than 5 times the upper limit of normal (ULN). Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis, hyperglycaemia, and bradycardia have also been reported.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral150 mg/1
Capsuleoral150 mg
Capsule, hardOral use150 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7153964 No2001-02-262021-02-26Us
US7893074 No2006-04-252026-04-25Us
US7964592 No2007-01-132027-01-13Us
US8039474 No2010-06-292030-06-29Us
US8039479 No2010-06-292030-06-29Us
US8377921 No2007-11-202027-11-20Us
US8703787 No2012-02-022032-02-02Us
US9309229 No2012-01-182032-01-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
pKa9.7 and 4.1FDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.00222 mg/mLALOGPS
logP5.23ALOGPS
logP5.81ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.58ChemAxon
pKa (Strongest Basic)10.07ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area105.24 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity153.86 m3·mol-1ChemAxon
Polarizability61.33 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference
  1. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26. Pubmed
General References
  1. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107. [PubMed:24670165 ]
  2. Nishio M, Murakami H, Horiike A, Takahashi T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, Robson M, Seto T: Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors. J Thorac Oncol. 2015 Jul;10(7):1058-66. doi: 10.1097/JTO.0000000000000566. [PubMed:26020125 ]
  3. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, Gray NS, Warmuth M: Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Epub 2006 Dec 21. [PubMed:17185414 ]
  4. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26. [PubMed:23742252 ]
  5. Mano H: The EML4-ALK oncogene: targeting an essential growth driver in human cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2015;91(5):193-201. doi: 10.2183/pjab.91.193. [PubMed:25971657 ]
External Links
ATC CodesL01XE28
AHFS Codes
  • 10:00
PDB Entries
FDA labelDownload (307 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hyperglycemic activities of Ceritinib.
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Ceritinib.
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Ceritinib.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ceritinib.
AcebutololAcebutolol may increase the bradycardic activities of Ceritinib.
AceclofenacThe serum concentration of Aceclofenac can be increased when it is combined with Ceritinib.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Ceritinib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Ceritinib.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ceritinib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ceritinib.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ceritinib.
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Ceritinib.
AfatinibThe serum concentration of Ceritinib can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Ceritinib.
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Ceritinib.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Ceritinib.
AlclometasoneAlclometasone may increase the hyperglycemic activities of Ceritinib.
AldosteroneAldosterone may increase the hyperglycemic activities of Ceritinib.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ceritinib.
AlectinibThe serum concentration of Ceritinib can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Ceritinib.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ceritinib.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Ceritinib.
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Ceritinib.
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Ceritinib.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Ceritinib.
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Ceritinib.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Ceritinib.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ceritinib.
AmantadineAmantadine may increase the QTc-prolonging activities of Ceritinib.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ceritinib.
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Ceritinib.
AmcinonideAmcinonide may increase the hyperglycemic activities of Ceritinib.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Ceritinib.
Aminohippuric acidThe serum concentration of Ceritinib can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Ceritinib.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Ceritinib.
AmiodaroneAmiodarone may increase the bradycardic activities of Ceritinib.
AmiodaroneCeritinib may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ceritinib.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Ceritinib.
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Ceritinib.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Ceritinib.
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Ceritinib.
AmprenavirThe serum concentration of Ceritinib can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Ceritinib can be increased when it is combined with Amsacrine.
AnagrelideCeritinib may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Ceritinib.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ceritinib.
ApomorphineApomorphine may increase the QTc-prolonging activities of Ceritinib.
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Ceritinib.
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Ceritinib.
Arachidonic AcidThe serum concentration of Arachidonic Acid can be increased when it is combined with Ceritinib.
ArformoterolThe serum concentration of Arformoterol can be increased when it is combined with Ceritinib.
ArformoterolArformoterol may increase the QTc-prolonging activities of Ceritinib.
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Ceritinib.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ceritinib.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Ceritinib.
Arsenic trioxideCeritinib may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherCeritinib may increase the QTc-prolonging activities of Artemether.
AsenapineCeritinib may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Ceritinib.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Ceritinib.
AtenololAtenolol may increase the bradycardic activities of Ceritinib.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Ceritinib.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ceritinib.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Ceritinib.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ceritinib.
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Ceritinib.
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Ceritinib.
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Ceritinib.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Ceritinib.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hyperglycemic activities of Ceritinib.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ceritinib.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Ceritinib.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Ceritinib.
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Ceritinib.
BenzocaineThe serum concentration of Ceritinib can be increased when it is combined with Benzocaine.
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Ceritinib.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Ceritinib.
BepridilThe serum concentration of Ceritinib can be increased when it is combined with Bepridil.
BeractantBeractant may increase the bradycardic activities of Ceritinib.
BetamethasoneBetamethasone may increase the hyperglycemic activities of Ceritinib.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ceritinib.
BetaxololBetaxolol may increase the bradycardic activities of Ceritinib.
BevacizumabBevacizumab may increase the cardiotoxic activities of Ceritinib.
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Ceritinib.
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Ceritinib.
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Ceritinib.
BiperidenThe serum concentration of Ceritinib can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the bradycardic activities of Ceritinib.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Ceritinib.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Ceritinib.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Ceritinib.
BortezomibBortezomib may increase the QTc-prolonging activities of Ceritinib.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ceritinib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ceritinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ceritinib.
BretyliumBretylium may increase the bradycardic activities of Ceritinib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Ceritinib.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Ceritinib.
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Ceritinib.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ceritinib.
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Ceritinib.
BudesonideBudesonide may increase the hyperglycemic activities of Ceritinib.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Ceritinib.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ceritinib.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Ceritinib.
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Ceritinib.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Ceritinib.
BuserelinBuserelin may increase the QTc-prolonging activities of Ceritinib.
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Ceritinib.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Ceritinib.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ceritinib.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ceritinib.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Ceritinib.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ceritinib.
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Ceritinib.
CalfactantCalfactant may increase the bradycardic activities of Ceritinib.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ceritinib.
CandesartanThe serum concentration of Candesartan can be increased when it is combined with Ceritinib.
CaptoprilThe serum concentration of Ceritinib can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Ceritinib.
CarbamazepineThe serum concentration of Ceritinib can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Ceritinib.
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Ceritinib.
CarteololCarteolol may increase the bradycardic activities of Ceritinib.
CarvedilolCarvedilol may increase the bradycardic activities of Ceritinib.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Ceritinib.
CaspofunginThe serum concentration of Ceritinib can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ceritinib.
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Ceritinib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Ceritinib.
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ceritinib.
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Ceritinib.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Ceritinib.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Ceritinib.
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Ceritinib.
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Ceritinib.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Ceritinib.
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Ceritinib.
ChlorprothixeneThe serum concentration of Ceritinib can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Ceritinib.
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Ceritinib.
CholesterolThe serum concentration of Ceritinib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Ceritinib can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Ceritinib.
CiclesonideCiclesonide may increase the hyperglycemic activities of Ceritinib.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ceritinib.
CilazaprilThe serum concentration of Ceritinib can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ceritinib.
CimetidineThe serum concentration of Ceritinib can be decreased when it is combined with Cimetidine.
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Ceritinib.
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Ceritinib.
CiprofloxacinCeritinib may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Ceritinib can be increased when it is combined with Ciprofloxacin.
CisaprideCeritinib may increase the QTc-prolonging activities of Cisapride.
CitalopramCeritinib may increase the QTc-prolonging activities of Citalopram.
CitalopramThe serum concentration of Ceritinib can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Ceritinib.
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Ceritinib.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ceritinib.
Clobetasol propionateClobetasol propionate may increase the hyperglycemic activities of Ceritinib.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Ceritinib.
ClocortoloneClocortolone may increase the hyperglycemic activities of Ceritinib.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Ceritinib.
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Ceritinib.
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Ceritinib.
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Ceritinib.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Ceritinib.
ClomipramineClomipramine may increase the QTc-prolonging activities of Ceritinib.
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Ceritinib.
ClonidineClonidine may increase the bradycardic activities of Ceritinib.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ceritinib.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ceritinib.
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Ceritinib.
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Ceritinib.
ClotrimazoleThe serum concentration of Ceritinib can be decreased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ceritinib.
ClozapineClozapine may increase the QTc-prolonging activities of Ceritinib.
CobicistatThe serum concentration of Ceritinib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ceritinib.
CocaineThe serum concentration of Cocaine can be increased when it is combined with Ceritinib.
CodeineThe serum concentration of Codeine can be increased when it is combined with Ceritinib.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ceritinib.
ColforsinThe serum concentration of Ceritinib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ceritinib.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ceritinib.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Ceritinib.
Cortisone acetateCortisone acetate may increase the hyperglycemic activities of Ceritinib.
CrizotinibCrizotinib may increase the bradycardic activities of Ceritinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ceritinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ceritinib.
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Ceritinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ceritinib.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ceritinib.
CyclosporineThe serum concentration of Ceritinib can be decreased when it is combined with Cyclosporine.
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Ceritinib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Ceritinib.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Ceritinib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Ceritinib.
DactinomycinThe serum concentration of Ceritinib can be increased when it is combined with Dactinomycin.
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Ceritinib.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ceritinib.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Ceritinib.
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Ceritinib.
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Ceritinib.
DarunavirThe serum concentration of Darunavir can be increased when it is combined with Ceritinib.
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Ceritinib.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Ceritinib.
DasatinibDasatinib may increase the QTc-prolonging activities of Ceritinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ceritinib.
DaunorubicinThe serum concentration of Ceritinib can be decreased when it is combined with Daunorubicin.
DegarelixDegarelix may increase the QTc-prolonging activities of Ceritinib.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Ceritinib.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hyperglycemic activities of Ceritinib.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hyperglycemic activities of Ceritinib.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Ceritinib.
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Ceritinib.
DesfluraneDesflurane may increase the QTc-prolonging activities of Ceritinib.
DesipramineDesipramine may increase the QTc-prolonging activities of Ceritinib.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ceritinib.
DesloratadineThe serum concentration of Ceritinib can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hyperglycemic activities of Ceritinib.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Ceritinib.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hyperglycemic activities of Ceritinib.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Ceritinib.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Ceritinib.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ceritinib.
DexamethasoneDexamethasone may increase the hyperglycemic activities of Ceritinib.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hyperglycemic activities of Ceritinib.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Ceritinib.
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Ceritinib.
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Ceritinib.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Ceritinib.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ceritinib.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Ceritinib.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Ceritinib.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Ceritinib.
DiflorasoneDiflorasone may increase the hyperglycemic activities of Ceritinib.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Ceritinib.
DifluocortoloneDifluocortolone may increase the hyperglycemic activities of Ceritinib.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Ceritinib.
DifluprednateDifluprednate may increase the hyperglycemic activities of Ceritinib.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Ceritinib.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ceritinib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ceritinib.
DigoxinDigoxin may increase the bradycardic activities of Ceritinib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ceritinib.
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Ceritinib.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Ceritinib.
DiltiazemDiltiazem may increase the bradycardic activities of Ceritinib.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Ceritinib.
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Ceritinib.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Ceritinib.
DipyridamoleThe serum concentration of Ceritinib can be increased when it is combined with Dipyridamole.
DisopyramideCeritinib may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Ceritinib.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ceritinib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ceritinib.
DofetilideCeritinib may increase the QTc-prolonging activities of Dofetilide.
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Ceritinib.
DolasetronDolasetron may increase the QTc-prolonging activities of Ceritinib.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ceritinib.
DonepezilDonepezil may increase the bradycardic activities of Ceritinib.
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Ceritinib.
DopamineThe serum concentration of Dopamine can be increased when it is combined with Ceritinib.
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Ceritinib.
DoxazosinThe serum concentration of Ceritinib can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ceritinib.
DoxepinDoxepin may increase the QTc-prolonging activities of Ceritinib.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ceritinib.
DoxorubicinThe serum concentration of Ceritinib can be decreased when it is combined with Doxorubicin.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ceritinib.
DronedaroneDronedarone may increase the bradycardic activities of Ceritinib.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Ceritinib.
DroperidolDroperidol may increase the QTc-prolonging activities of Ceritinib.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Ceritinib.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ceritinib.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Ceritinib.
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Ceritinib.
ElbasvirThe serum concentration of Ceritinib can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ceritinib.
EliglustatCeritinib may increase the QTc-prolonging activities of Eliglustat.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Ceritinib.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Ceritinib.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Ceritinib.
EnzalutamideThe serum concentration of Ceritinib can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ceritinib.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Ceritinib.
EpoprostenolThe serum concentration of Epoprostenol can be increased when it is combined with Ceritinib.
EquileninEquilenin may increase the hyperglycemic activities of Ceritinib.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Ceritinib.
EquilinEquilin may increase the hyperglycemic activities of Ceritinib.
EquilinThe serum concentration of Equilin can be increased when it is combined with Ceritinib.
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Ceritinib.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ceritinib.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ceritinib.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ceritinib.
EribulinEribulin may increase the QTc-prolonging activities of Ceritinib.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ceritinib.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Ceritinib.
ErythromycinThe serum concentration of Ceritinib can be decreased when it is combined with Erythromycin.
EscitalopramCeritinib may increase the QTc-prolonging activities of Escitalopram.
EsmololEsmolol may increase the bradycardic activities of Ceritinib.
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Ceritinib.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Ceritinib.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ceritinib.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Ceritinib.
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Ceritinib.
EstriolThe serum concentration of Ceritinib can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Estrone can be increased when it is combined with Ceritinib.
EstroneEstrone may increase the hyperglycemic activities of Ceritinib.
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Ceritinib.
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Ceritinib.
EthanolThe serum concentration of Ethanol can be increased when it is combined with Ceritinib.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ceritinib.
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Ceritinib.
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Ceritinib.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Ceritinib.
EtodolacThe serum concentration of Etodolac can be increased when it is combined with Ceritinib.
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Ceritinib.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ceritinib.
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Ceritinib.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Ceritinib.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ceritinib.
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Ceritinib.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Ceritinib.
EzogabineEzogabine may increase the QTc-prolonging activities of Ceritinib.
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Ceritinib.
FamotidineFamotidine may increase the QTc-prolonging activities of Ceritinib.
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Ceritinib.
FelbamateFelbamate may increase the QTc-prolonging activities of Ceritinib.
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Ceritinib.
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Ceritinib.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Ceritinib.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ceritinib.
FexofenadineThe serum concentration of Ceritinib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Ceritinib can be increased when it is combined with Fidaxomicin.
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Ceritinib.
FingolimodFingolimod may increase the bradycardic activities of Ceritinib.
FingolimodThe serum concentration of Fingolimod can be increased when it is combined with Ceritinib.
FlecainideFlecainide may increase the QTc-prolonging activities of Ceritinib.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ceritinib.
FluconazoleFluconazole may increase the QTc-prolonging activities of Ceritinib.
FludrocortisoneFludrocortisone may increase the hyperglycemic activities of Ceritinib.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Ceritinib.
FlumethasoneFlumethasone may increase the hyperglycemic activities of Ceritinib.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Ceritinib.
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Ceritinib.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Ceritinib.
FlunisolideFlunisolide may increase the hyperglycemic activities of Ceritinib.
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Ceritinib.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hyperglycemic activities of Ceritinib.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ceritinib.
FluocinonideFluocinonide may increase the hyperglycemic activities of Ceritinib.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Ceritinib.
FluocortoloneFluocortolone may increase the hyperglycemic activities of Ceritinib.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Ceritinib.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Ceritinib.
FluorometholoneFluorometholone may increase the hyperglycemic activities of Ceritinib.
FluoxetineCeritinib may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe serum concentration of Ceritinib can be increased when it is combined with Fluoxetine.
FlupentixolCeritinib may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe serum concentration of Ceritinib can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Ceritinib can be increased when it is combined with Fluphenazine.
FluprednideneFluprednidene may increase the hyperglycemic activities of Ceritinib.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Ceritinib.
FluprednisoloneFluprednisolone may increase the hyperglycemic activities of Ceritinib.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Ceritinib.
FlurandrenolideFlurandrenolide may increase the hyperglycemic activities of Ceritinib.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Ceritinib.
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Ceritinib.
FlurbiprofenThe serum concentration of Flurbiprofen can be increased when it is combined with Ceritinib.
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Ceritinib.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ceritinib.
Fluticasone furoateFluticasone furoate may increase the hyperglycemic activities of Ceritinib.
Fluticasone PropionateFluticasone Propionate may increase the hyperglycemic activities of Ceritinib.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ceritinib.
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ceritinib.
FluvoxamineThe serum concentration of Ceritinib can be increased when it is combined with Fluvoxamine.
FormoterolThe serum concentration of Formoterol can be increased when it is combined with Ceritinib.
FormoterolFormoterol may increase the QTc-prolonging activities of Ceritinib.
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Ceritinib.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ceritinib.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Ceritinib.
FosphenytoinThe serum concentration of Ceritinib can be decreased when it is combined with Fosphenytoin.
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Ceritinib.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ceritinib.
GalantamineGalantamine may increase the bradycardic activities of Ceritinib.
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Ceritinib.
GavestinelThe serum concentration of Gavestinel can be increased when it is combined with Ceritinib.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ceritinib.
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Ceritinib.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Ceritinib.
GenisteinThe serum concentration of Ceritinib can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ceritinib.
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Ceritinib.
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Ceritinib.
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Ceritinib.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ceritinib.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Ceritinib.
GlycerolThe serum concentration of Ceritinib can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Ceritinib.
Gramicidin DThe serum concentration of Ceritinib can be increased when it is combined with Gramicidin D.
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Ceritinib.
GranisetronGranisetron may increase the QTc-prolonging activities of Ceritinib.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ceritinib.
GuanfacineGuanfacine may increase the bradycardic activities of Ceritinib.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Ceritinib.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Ceritinib.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Ceritinib.
HalothaneThe serum concentration of Halothane can be increased when it is combined with Ceritinib.
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Ceritinib.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be increased when it is combined with Ceritinib.
HistrelinHistrelin may increase the QTc-prolonging activities of Ceritinib.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Ceritinib.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ceritinib.
HydrocortisoneHydrocortisone may increase the hyperglycemic activities of Ceritinib.
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Ceritinib.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Ceritinib.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Ceritinib.
IbandronateIbandronate may increase the QTc-prolonging activities of Ceritinib.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ceritinib.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ceritinib.
IbutilideCeritinib may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe serum concentration of Idarubicin can be increased when it is combined with Ceritinib.
IdelalisibThe serum concentration of Ceritinib can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Ceritinib.
IloperidoneCeritinib may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ceritinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Ceritinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ceritinib.
ImipramineImipramine may increase the QTc-prolonging activities of Ceritinib.
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Ceritinib.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ceritinib.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Ceritinib.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Ceritinib.
IndapamideIndapamide may increase the QTc-prolonging activities of Ceritinib.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Ceritinib.
indisulamThe serum concentration of indisulam can be increased when it is combined with Ceritinib.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Ceritinib.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ceritinib.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ceritinib.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ceritinib.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ceritinib.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ceritinib.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ceritinib.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Ceritinib.
IrbesartanThe serum concentration of Irbesartan can be increased when it is combined with Ceritinib.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Ceritinib.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Ceritinib.
IsavuconazoniumThe serum concentration of Ceritinib can be increased when it is combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Ceritinib.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ceritinib.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Ceritinib.
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Ceritinib.
IsradipineIsradipine may increase the QTc-prolonging activities of Ceritinib.
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Ceritinib.
IvabradineIvabradine may increase the QTc-prolonging activities of Ceritinib.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Ceritinib.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Ceritinib.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ceritinib.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Ceritinib.
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Ceritinib.
KetamineThe serum concentration of Ketamine can be increased when it is combined with Ceritinib.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ceritinib.
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Ceritinib.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Ceritinib.
KetoprofenThe serum concentration of Ketoprofen can be increased when it is combined with Ceritinib.
LabetalolLabetalol may increase the bradycardic activities of Ceritinib.
LacosamideCeritinib may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideLanreotide may increase the bradycardic activities of Ceritinib.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ceritinib.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Ceritinib.
LapatinibLapatinib may increase the QTc-prolonging activities of Ceritinib.
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Ceritinib.
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Ceritinib.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ceritinib.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Ceritinib.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Ceritinib.
LesinuradThe serum concentration of Lesinurad can be increased when it is combined with Ceritinib.
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Ceritinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ceritinib.
LevobunololLevobunolol may increase the bradycardic activities of Ceritinib.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Ceritinib.
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Ceritinib.
LevofloxacinCeritinib may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Ceritinib can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Ceritinib.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ceritinib.
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Ceritinib.
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Ceritinib.
LevothyroxineThe serum concentration of Ceritinib can be decreased when it is combined with Levothyroxine.
LicofeloneThe serum concentration of Licofelone can be increased when it is combined with Ceritinib.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Ceritinib.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Ceritinib.
LiothyronineThe serum concentration of Ceritinib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Ceritinib can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ceritinib.
LisinoprilThe serum concentration of Ceritinib can be increased when it is combined with Lisinopril.
LisurideThe serum concentration of Lisuride can be increased when it is combined with Ceritinib.
LithiumLithium may increase the QTc-prolonging activities of Ceritinib.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ceritinib.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ceritinib.
LopinavirThe serum concentration of Ceritinib can be increased when it is combined with Lopinavir.
LopinavirCeritinib may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Ceritinib.
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Ceritinib.
LornoxicamThe serum concentration of Lornoxicam can be increased when it is combined with Ceritinib.
LosartanThe serum concentration of Losartan can be increased when it is combined with Ceritinib.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ceritinib.
LucinactantLucinactant may increase the bradycardic activities of Ceritinib.
LumacaftorThe serum concentration of Ceritinib can be decreased when it is combined with Lumacaftor.
LumefantrineCeritinib may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Ceritinib.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Ceritinib.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Ceritinib.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Ceritinib.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Ceritinib.
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Ceritinib.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ceritinib.
MedrysoneMedrysone may increase the hyperglycemic activities of Ceritinib.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Ceritinib.
Mefenamic acidThe serum concentration of Mefenamic acid can be increased when it is combined with Ceritinib.
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Ceritinib.
MefloquineMefloquine may increase the QTc-prolonging activities of Ceritinib.
Megestrol acetateThe serum concentration of Ceritinib can be increased when it is combined with Megestrol acetate.
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Ceritinib.
MelengestrolMelengestrol may increase the hyperglycemic activities of Ceritinib.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Ceritinib.
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Ceritinib.
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Ceritinib.
MeprobamateThe serum concentration of Ceritinib can be increased when it is combined with Meprobamate.
MestranolThe serum concentration of Mestranol can be increased when it is combined with Ceritinib.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Ceritinib.
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Ceritinib.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Ceritinib.
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Ceritinib.
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Ceritinib.
MethyldopaMethyldopa may increase the bradycardic activities of Ceritinib.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ceritinib.
MethylprednisoloneMethylprednisolone may increase the hyperglycemic activities of Ceritinib.
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Ceritinib.
MetipranololMetipranolol may increase the bradycardic activities of Ceritinib.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Ceritinib.
MetoprololMetoprolol may increase the bradycardic activities of Ceritinib.
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Ceritinib.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Ceritinib.
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Ceritinib.
MianserinThe serum concentration of Mianserin can be increased when it is combined with Ceritinib.
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Ceritinib.
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Ceritinib.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ceritinib.
MidazolamThe serum concentration of Ceritinib can be decreased when it is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Ceritinib.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ceritinib.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ceritinib.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ceritinib.
MirabegronMirabegron may increase the QTc-prolonging activities of Ceritinib.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Ceritinib.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Ceritinib.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ceritinib.
MitomycinThe serum concentration of Ceritinib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Ceritinib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Ceritinib can be decreased when it is combined with Mitoxantrone.
MoclobemideThe serum concentration of Moclobemide can be increased when it is combined with Ceritinib.
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Ceritinib.
MoexiprilMoexipril may increase the QTc-prolonging activities of Ceritinib.
MometasoneMometasone may increase the hyperglycemic activities of Ceritinib.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Ceritinib.
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Ceritinib.
MorphineThe serum concentration of Morphine can be increased when it is combined with Ceritinib.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Ceritinib.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ceritinib.
NadololNadolol may increase the bradycardic activities of Ceritinib.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ceritinib.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ceritinib.
NaltrexoneThe serum concentration of Ceritinib can be increased when it is combined with Naltrexone.
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Ceritinib.
NaringeninThe serum concentration of Ceritinib can be increased when it is combined with Naringenin.
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Ceritinib.
NebivololNebivolol may increase the bradycardic activities of Ceritinib.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Ceritinib.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Ceritinib.
NeostigmineThe serum concentration of Ceritinib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Netupitant can be increased when it is combined with Ceritinib.
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Ceritinib.
NevirapineThe serum concentration of Ceritinib can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Ceritinib.
NicardipineNicardipine may increase the QTc-prolonging activities of Ceritinib.
NiclosamideThe serum concentration of Niclosamide can be increased when it is combined with Ceritinib.
NicotineThe serum concentration of Nicotine can be increased when it is combined with Ceritinib.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ceritinib.
NifedipineThe serum concentration of Ceritinib can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ceritinib.
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Ceritinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ceritinib.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Ceritinib.
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Ceritinib.
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Ceritinib.
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Ceritinib.
NorethisteroneThe serum concentration of Ceritinib can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ceritinib.
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Ceritinib.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Ceritinib.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Ceritinib.
OctreotideOctreotide may increase the bradycardic activities of Ceritinib.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Ceritinib.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Ceritinib.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Ceritinib.
OlodaterolThe serum concentration of Olodaterol can be increased when it is combined with Ceritinib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Ceritinib.
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Ceritinib.
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Ceritinib.
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Ceritinib.
OndansetronOndansetron may increase the QTc-prolonging activities of Ceritinib.
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Ceritinib.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Ceritinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Ceritinib.
OuabainOuabain may decrease the cardiotoxic activities of Ceritinib.
OxaprozinThe serum concentration of Oxaprozin can be increased when it is combined with Ceritinib.
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Ceritinib.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Ceritinib.
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Ceritinib.
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Ceritinib.
OxytocinOxytocin may increase the QTc-prolonging activities of Ceritinib.
P-NitrophenolThe serum concentration of Ceritinib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ceritinib.
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Ceritinib.
PaliperidoneCeritinib may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Ceritinib can be increased when it is combined with Palmitic Acid.
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Ceritinib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ceritinib.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Ceritinib.
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Ceritinib.
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Ceritinib.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Ceritinib.
ParamethasoneParamethasone may increase the hyperglycemic activities of Ceritinib.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Ceritinib.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Ceritinib.
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Ceritinib.
ParoxetineParoxetine may increase the QTc-prolonging activities of Ceritinib.
PasireotidePasireotide may increase the bradycardic activities of Ceritinib.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ceritinib.
PazopanibPazopanib may increase the QTc-prolonging activities of Ceritinib.
PenbutololPenbutolol may increase the bradycardic activities of Ceritinib.
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Ceritinib.
PentamidinePentamidine may increase the QTc-prolonging activities of Ceritinib.
PentobarbitalThe serum concentration of Ceritinib can be decreased when it is combined with Pentobarbital.
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Ceritinib.
PerflutrenPerflutren may increase the QTc-prolonging activities of Ceritinib.
PergolideThe serum concentration of Pergolide can be increased when it is combined with Ceritinib.
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Ceritinib.
PerindoprilThe serum concentration of Ceritinib can be increased when it is combined with Perindopril.
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Ceritinib.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Ceritinib.
PethidineThe serum concentration of Pethidine can be increased when it is combined with Ceritinib.
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Ceritinib.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Ceritinib.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Ceritinib.
PhenobarbitalThe serum concentration of Ceritinib can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Ceritinib.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Ceritinib.
PhenylbutazoneThe serum concentration of Phenylbutazone can be increased when it is combined with Ceritinib.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ceritinib.
PhenytoinThe serum concentration of Ceritinib can be decreased when it is combined with Phenytoin.
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Ceritinib.
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Ceritinib.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ceritinib.
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Ceritinib.
PindololPindolol may increase the bradycardic activities of Ceritinib.
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Ceritinib.
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Ceritinib.
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Ceritinib.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ceritinib.
Platelet Activating FactorThe serum concentration of Ceritinib can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Ceritinib.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ceritinib.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ceritinib.
Poractant alfaPoractant alfa may increase the bradycardic activities of Ceritinib.
PosaconazoleThe serum concentration of Posaconazole can be increased when it is combined with Ceritinib.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ceritinib.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Ceritinib.
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Ceritinib.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ceritinib.
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Ceritinib.
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Ceritinib.
PrazosinThe serum concentration of Ceritinib can be increased when it is combined with Prazosin.
PrednicarbatePrednicarbate may increase the hyperglycemic activities of Ceritinib.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Ceritinib.
PrednisolonePrednisolone may increase the hyperglycemic activities of Ceritinib.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ceritinib.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ceritinib.
PrednisonePrednisone may increase the hyperglycemic activities of Ceritinib.
PregnenolonePregnenolone may increase the hyperglycemic activities of Ceritinib.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Ceritinib.
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Ceritinib.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Ceritinib.
PrimidoneThe serum concentration of Ceritinib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Ceritinib can be increased when it is combined with Probenecid.
ProcainamideCeritinib may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Ceritinib.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ceritinib.
ProgesteroneThe serum concentration of Ceritinib can be decreased when it is combined with Progesterone.
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Ceritinib.
PromazineThe serum concentration of Promazine can be increased when it is combined with Ceritinib.
PromazinePromazine may increase the QTc-prolonging activities of Ceritinib.
PromethazinePromethazine may increase the QTc-prolonging activities of Ceritinib.
PropafenonePropafenone may increase the bradycardic activities of Ceritinib.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Ceritinib.
PropofolThe serum concentration of Propofol can be increased when it is combined with Ceritinib.
PropofolPropofol may increase the QTc-prolonging activities of Ceritinib.
PropranololPropranolol may increase the bradycardic activities of Ceritinib.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Ceritinib.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Ceritinib.
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Ceritinib.
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Ceritinib.
QuercetinThe serum concentration of Ceritinib can be increased when it is combined with Quercetin.
QuetiapineCeritinib may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Ceritinib.
QuinidineCeritinib may increase the QTc-prolonging activities of Quinidine.
QuinidineThe serum concentration of Ceritinib can be increased when it is combined with Quinidine.
QuinineCeritinib may increase the QTc-prolonging activities of Quinine.
QuinineThe serum concentration of Ceritinib can be increased when it is combined with Quinine.
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Ceritinib.
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Ceritinib.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Ceritinib.
RanitidineThe serum concentration of Ceritinib can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ceritinib can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Ceritinib.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Ceritinib.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Ceritinib.
ReserpineThe serum concentration of Ceritinib can be decreased when it is combined with Reserpine.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Ceritinib.
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Ceritinib.
RifabutinThe serum concentration of Ceritinib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Ceritinib.
RifampicinThe serum concentration of Ceritinib can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Ceritinib can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Ceritinib.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Ceritinib.
RimexoloneRimexolone may increase the hyperglycemic activities of Ceritinib.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Ceritinib.
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Ceritinib.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Ceritinib.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ceritinib.
RisperidoneRisperidone may increase the QTc-prolonging activities of Ceritinib.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Ceritinib.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ceritinib.
RivastigmineRivastigmine may increase the bradycardic activities of Ceritinib.
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Ceritinib.
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Ceritinib.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ceritinib.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Ceritinib.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Ceritinib.
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Ceritinib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ceritinib.
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Ceritinib.
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Ceritinib.
RuxolitinibRuxolitinib may increase the bradycardic activities of Ceritinib.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Ceritinib.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Ceritinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ceritinib.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Ceritinib.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Ceritinib.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Ceritinib.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Ceritinib.
ScopolamineThe serum concentration of Ceritinib can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Ceritinib.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ceritinib.
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Ceritinib.
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Ceritinib.
SertralineThe serum concentration of Sertraline can be increased when it is combined with Ceritinib.
SertralineSertraline may increase the QTc-prolonging activities of Ceritinib.
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Ceritinib.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Ceritinib.
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Ceritinib.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Ceritinib.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ceritinib.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ceritinib.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ceritinib.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Ceritinib.
SirolimusThe serum concentration of Ceritinib can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ceritinib.
SitaxentanThe serum concentration of Sitaxentan can be increased when it is combined with Ceritinib.
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Ceritinib.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Ceritinib.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Ceritinib.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ceritinib.
SorafenibSorafenib may increase the QTc-prolonging activities of Ceritinib.
SotalolSotalol may increase the bradycardic activities of Ceritinib.
SotalolCeritinib may increase the QTc-prolonging activities of Sotalol.
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Ceritinib.
SpironolactoneThe serum concentration of Ceritinib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Ceritinib can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Ceritinib can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Ceritinib can be decreased when it is combined with Streptozocin.
SufentanilSufentanil may increase the bradycardic activities of Ceritinib.
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Ceritinib.
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Ceritinib.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Ceritinib.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Ceritinib.
SulfamoxoleThe serum concentration of Sulfamoxole can be increased when it is combined with Ceritinib.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Ceritinib.
SulfisoxazoleThe serum concentration of Sulfisoxazole can be increased when it is combined with Ceritinib.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Ceritinib.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ceritinib.
SumatriptanThe serum concentration of Ceritinib can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Ceritinib.
SunitinibSunitinib may increase the QTc-prolonging activities of Ceritinib.
SuprofenThe serum concentration of Suprofen can be increased when it is combined with Ceritinib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Ceritinib.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Ceritinib.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Ceritinib.
TacrineThe serum concentration of Ceritinib can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ceritinib.
TacrolimusThe serum concentration of Ceritinib can be decreased when it is combined with Tacrolimus.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Ceritinib.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ceritinib.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Ceritinib.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Ceritinib.
TapentadolThe serum concentration of Tapentadol can be increased when it is combined with Ceritinib.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Ceritinib.
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Ceritinib.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Ceritinib.
Taurocholic AcidThe serum concentration of Ceritinib can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Ceritinib.
TelavancinTelavancin may increase the QTc-prolonging activities of Ceritinib.
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Ceritinib.
TelmisartanThe serum concentration of Ceritinib can be increased when it is combined with Telmisartan.
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Ceritinib.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ceritinib.
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Ceritinib.
TenoxicamThe serum concentration of Tenoxicam can be increased when it is combined with Ceritinib.
TerazosinThe serum concentration of Ceritinib can be increased when it is combined with Terazosin.
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Ceritinib.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ceritinib.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Ceritinib.
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Ceritinib.
TesmilifeneThe serum concentration of Ceritinib can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Ceritinib.
TetrabenazineCeritinib may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Ceritinib.
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Ceritinib.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Ceritinib.
ThiamylalThe serum concentration of Thiamylal can be increased when it is combined with Ceritinib.
ThioridazineCeritinib may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Ceritinib.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Ceritinib.
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Ceritinib.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ceritinib resulting in a loss in efficacy.
TicagrelorThe serum concentration of Ceritinib can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Ceritinib.
TimololTimolol may increase the bradycardic activities of Ceritinib.
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Ceritinib.
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Ceritinib.
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Ceritinib.
TixocortolTixocortol may increase the hyperglycemic activities of Ceritinib.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Ceritinib.
TizanidineTizanidine may increase the bradycardic activities of Ceritinib.
TofacitinibTofacitinib may increase the bradycardic activities of Ceritinib.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Ceritinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ceritinib.
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Ceritinib.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Ceritinib.
TolterodineTolterodine may increase the QTc-prolonging activities of Ceritinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ceritinib.
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Ceritinib.
ToremifeneThe risk or severity of adverse effects can be increased when Ceritinib is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Ceritinib.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Ceritinib.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ceritinib.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Ceritinib.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Ceritinib.
TrazodoneTrazodone may increase the QTc-prolonging activities of Ceritinib.
TreprostinilThe serum concentration of Treprostinil can be increased when it is combined with Ceritinib.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Ceritinib.
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Ceritinib.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Ceritinib.
TriamcinoloneTriamcinolone may increase the hyperglycemic activities of Ceritinib.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ceritinib.
TrifluoperazineThe serum concentration of Ceritinib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Ceritinib can be increased when it is combined with Triflupromazine.
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Ceritinib.
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Ceritinib.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Ceritinib.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ceritinib.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Ceritinib.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ceritinib.
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Ceritinib.
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Ceritinib.
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Ceritinib.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ceritinib.
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Ceritinib.
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Ceritinib.
ValsartanThe serum concentration of Valsartan can be increased when it is combined with Ceritinib.
VandetanibCeritinib may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Ceritinib.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Ceritinib.
VardenafilVardenafil may increase the QTc-prolonging activities of Ceritinib.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Ceritinib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ceritinib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Ceritinib.
VerapamilVerapamil may increase the bradycardic activities of Ceritinib.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Ceritinib.
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Ceritinib.
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Ceritinib.
VilanterolVilanterol may increase the QTc-prolonging activities of Ceritinib.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Ceritinib.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ceritinib.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ceritinib.
VinblastineThe serum concentration of Ceritinib can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ceritinib.
VincristineThe serum concentration of Ceritinib can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Ceritinib.
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Ceritinib.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ceritinib.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ceritinib.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Ceritinib.
VoriconazoleThe serum concentration of Voriconazole can be increased when it is combined with Ceritinib.
VorinostatVorinostat may increase the QTc-prolonging activities of Ceritinib.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Ceritinib.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Ceritinib.
XimelagatranThe serum concentration of Ximelagatran can be increased when it is combined with Ceritinib.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Ceritinib.
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Ceritinib.
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Ceritinib.
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Ceritinib.
ZaltoprofenThe serum concentration of Zaltoprofen can be increased when it is combined with Ceritinib.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ceritinib.
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Ceritinib.
ZimelidineThe serum concentration of Ceritinib can be increased when it is combined with Zimelidine.
ZiprasidoneCeritinib may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Ceritinib.
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Ceritinib.
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Ceritinib.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Ceritinib.
ZuclopenthixolCeritinib may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost...
Gene Name:
ALK
Uniprot ID:
Q9UM73
Molecular Weight:
176440.535 Da
References
  1. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, Gray NS, Warmuth M: Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Epub 2006 Dec 21. [PubMed:17185414 ]
  2. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26. [PubMed:23742252 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on May 11, 2015 16:20 / Updated on September 28, 2016 03:24